Stock Market Update - May 20, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. HCWB - HCW Biologics Inc.
Price: $2.43 | Change: +129.25% ($1.37)
HCWB soared with an impressive 129.25% gain, largely fueled by a stellar first quarter for HCW Biologics Inc. The company reported a significant turnaround in Q1 2026, swinging to a net income of $3.5 million from a loss in the prior year, and handily beating analyst expectations for earnings per share.
A major catalyst for this financial surge was the announcement of a new, exclusive worldwide licensing agreement. This deal, focused on a promising immunotherapeutic targeting solid tumors, brought in a substantial $7 million in upfront fees, combining cash and an equity interest. This agreement dramatically boosted HCWB's total revenue to over $6.5 million, a massive leap from just a few thousand dollars the previous year.
The positive news also included updates on their drug pipeline, with a key treatment for alopecia areata progressing in clinical trials. Following these announcements, shares saw immediate and dramatic increases, at one point surging over 300% in intraday trading. What’s interesting here is how quickly the market reacted to the combination of strong financial performance and a strategic licensing win, even as the company acknowledged ongoing financial risks.
2. SLXN - Silexion Therapeutics Ltd.
Price: $0.5298 | Change: +96.95% ($0.2608)
SLXN just soared an impressive 96.95%! Silexion Therapeutics Ltd. saw its stock nearly double around May 21, 2026, primarily driven by exciting advancements in its lead cancer therapy, SIL204. This drug, an RNA interference therapy targeting KRAS-driven pancreatic cancer, received key approvals to begin its Phase 2/3 clinical trial in Israel and is expanding into Europe with a planned multi-country trial.
Adding to the positive momentum, preliminary lab results showed the drug could improve immune responses, hinting at future combination therapies. The company also secured $1 million in financing, which not only boosted its near-term cash position but also helped it maintain its Nasdaq listing by meeting minimum equity requirements. Despite reporting a wider net loss for Q1 2026, these significant clinical and financial milestones were enough to send the stock surging, showing how major drug development progress can capture investor attention.
3. GCL - GCL Global Holdings Ltd Ordinary Shares
Price: $0.7445 | Change: +72.46% ($0.3128)
GCL surged 72.46% recently following news of a significant strategic investment in its gaming subsidiary. ADATA Technology, a prominent maker of memory and gaming hardware, announced an additional $10 million investment into GCL's publishing arm, 4Divinity Pte. Ltd.
This latest injection brings ADATA's total commitment to 4Divinity to $23 million since December 2025. The capital is set to accelerate 4Divinity's growth by securing high-profile global game titles and enhancing its international publishing business. What makes this particularly interesting is the planned synergy: ADATA's hardware innovation will combine with 4Divinity's gaming content, aiming to create fresh experiences for gamers and driving significant investor optimism for GCL.
4. PHGE - BiomX Inc.
Price: $0.5969 | Change: +59.60% ($0.2229)
PHGE recently saw a remarkable 59.60% gain. BiomX Inc. (PHGE) stock has been climbing, not for its original biopharmaceutical work, but due to a significant strategic shift into defense, security, and critical-infrastructure technology. This bold pivot is being executed through a series of key acquisitions and new product launches.
The company's new direction is anchored by the acquisitions of Zorronet, an Israeli AI defense tech firm, and a controlling stake in DR. Frucht Systems (DFSL), which develops LADAR-based detection systems. These moves lay the groundwork for BiomX's focus on areas like counter-UAS and AI surveillance. Further bolstering market sentiment, BiomX's Zorronet subsidiary launched a secure mobile app for AI-driven command and control, already seeing active pilot programs with major defense entities.
What's particularly interesting is how the market is reacting to this aggressive shift. Despite BiomX reporting a net loss and expressing "substantial doubt" about its ability to continue as a going concern in Q1 2026, investors appear to be focusing heavily on the potential for new revenue streams and growth in the defense technology sector, signaling a strong belief in the company's new vision.
5. MTVA - MetaVia Inc.
Price: $2.89 | Change: +53.72% ($1.01)
MTVA recently jumped an impressive 53.72%. MetaVia Inc. saw this significant rise, primarily driven by exciting news ahead of a major medical conference and the publication of new research. The biggest catalyst is their upcoming presentations at the American Diabetes Association's (ADA) 2026 Scientific Sessions in early June.
These presentations will highlight MetaVia's drug candidates for challenging conditions like obesity and a serious liver disease called MASH. Key among them are DA-1726, a treatment for obesity and MASH, and vanoglipel, which targets liver fibrosis and type 2 diabetes. Further boosting confidence, MetaVia also published preclinical research showing vanoglipel's potential to reduce liver scarring.
What makes this particularly interesting is the high visibility these assets are getting in incredibly active therapeutic areas, such as obesity and diabetes, which are attracting significant investor attention.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.